.Nature Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after a mean follow-up of 11 months, individuals with metastatic stomach growths that got biomarker-matched therapies based on circulating lump DNA profiling revealed a more significant scientific perk than those receiving unparalleled treatment.